Navigation Links
US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
Date:3/28/2013

Denton, TX (PRWEB) March 28, 2013

US Radiopharmaceuticals (USR) announced today that it has awarded Von Gahlen International the contract to design, develop, and install the hot cells and ancillary equipment to be utilized in its USR Denton Tc-99m generator facility scheduled for opening in early 2014. Located in Chatsworth, GA, Von Gahlen is recognized as the industry leader in lead shielded products for the nuclear medicine industry that meets or exceeds industry standards and federal and state safety requirements.

In 2012, USR and the Australian Nuclear Science and Technology Organisation (ANSTO) entered into an exclusive license agreement to enable USR to manufacture the Australian designed Tc-99m generators, which utilize molybdenum-99 (Mo-99). The 20-year agreement represents the start of a long-term strategic partnership, between ANSTO and US Radiopharmaceuticals that will lead to the establishment of a high capacity production facility at the existing USR manufacturing site in Denton, Texas. The agreement allows for the exclusive distribution of the ANSTO generator in the Americas. The new line will be capable of producing up to 90% of the demand for Tc-99m throughout North and South America.

Under the terms of the agreement, USR will become the only U.S. generator manufacturer to exclusively use Mo-99 produced from Low Enriched Uranium (LEU) in all of their generators. In addition, USR has signed an agreement for the supply of Mo-99 to load these generators. ANSTO and its’ partner NTP of South Africa, are committed to meet the supply requirements of USR for Mo-99 once their facility is operational. This Mo-99 sourced from the ANSTO Open Pool Australian Lightwater (OPAL) reactor in Australia and the NTP Radioisotopes SAFARI-1 reactor in South Africa will be produced solely using LEU.

The ANSTO generators, having been used routinely in Australia and other countries for over 30 years, are fully compatible with current usage practices in the United States. “It is a major milestone for ANSTO to be able to deliver our domestic technology into the U.S. market. ANSTO has always been an LEU Mo-99 producer and is currently expanding its local production capacity. We have many years of demonstrated robust and reliable LEU Mo-99 production so ANSTO was an obvious partner for USR’s business plans”, said ANSTO CEO, Dr. Adi Paterson.

“This supply chain will maintain operating efficiencies for the pharmacy and medical service providers, as they will be assured of a stable supply and competitive pricing. The USR - ANSTO 18Ci LEU generators will be unaffected by costs incurred by current reactor operators upgrading their reactors from HEU to LEU production, the loss of current subsidies to their suppliers, and proposed federal tariffs for HEU products imported after 2016”, said USR CEO, Paul Crowe.

About US Radiopharmaceuticals

USR, located in Denton, Texas, is an emerging manufacturer and distributor of licensed radioisotopes and radiopharmaceuticals for the domestic and international nuclear medicine and molecular imaging communities. The company’s cGMP 85,000 Sq. ft. facility and high-energy accelerators offer manufacturing of traditional SPECT/PET radiopharmaceuticals and contract R&D manufacturing capabilities.

About ANSTO

ANSTO is Australia’s national nuclear research organisation and the center of Australian nuclear expertise. ANSTO operates nuclear science and technology based facilities, including Australia’s nuclear research reactor, OPAL. On average, each week ANSTO delivers 10,000 patient doses of potentially lifesaving nuclear medicines to over 250 partner hospitals and medical practices across Australia, New Zealand, and South East Asia.

About Von Gahlen

Von Gahlen is a modern state-of-the-art manufacturer of lead shielding products. Since its founding in 1973, Von Gahlen has become the industry leader in lead shielding, providing the nuclear medicine community with reliable, high quality products that meet or exceed industry standards and safety requirements. Von Gahlen installations may be found all over the world, including many of the largest turnkey installations in the field. Products include hot cells for positron emission tomography (PET), lead shields for environmental monitoring, shielding for isotope production facilities, transportation vials for radiopharmaceuticals, lead collimators for gamma cameras, and custom designed shielding.

For more information, please visit http://usradiopharma.us/

Read the full story at http://www.prweb.com/releases/2013/3/prweb10545122.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
2. USP Global Fellowship Awards Program Call for Applications
3. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
4. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
5. TriLink BioTechnologies Awards Keck Science Department ResearchReward
6. Young Pathologists Receive Awards for Research
7. National Non-Profit Awards Audio Conferencing to SoundConnect
8. Brain Research Foundation 2013 Scientific Innovations Awards To Dr. Jean Hebert and Dr. Brian Litt
9. Nerium Recaps the 44th Annual NAACP Image Awards
10. Molecular Medicine Awards 1st Annual Ross Prize to NYU Researcher
11. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 A Europe-wide survey ... that researchers using animals in their research treat them with due ... countries, and detailed analysis of the results indicates that there is ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... SAN FRANCISCO , Feb. 27, 2017 ... Spain has been appointed as ... Biopsy System. The IsoFlux system will be used in ... mutations relevant to lung and colon cancer, with plans ... developed. The laboratory is utilizing Fluxion,s IsoFlux System to ...
(Date:2/24/2017)... ... February 24, 2017 , ... A ... safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported ... two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on the ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
Breaking Biology Technology:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):